ABBVIE INC

AbbVie expands its medical‑aesthetics leadership—new SkinMedica barrier creams, hyaluronic‑acid mists, and a proven injectable portfolio drive innovation and market growth.

AbbVie’s EMA bid for SKYRIZI’s sub‑cutaneous Crohn’s therapy promises patient‑friendly dosing, strong Phase‑3 data and a €120 M revenue lift—while navigating competitive and reimbursement hurdles.

AbbVie’s new ABBV‑295 obesity drug faces a pivotal phase‑two trial, while Ken Griffin’s stake boosts its dividend‑rich profile—revealing investor confidence and a strategic path to market success.

Discover why AbbVie is outperforming biopharma peers: strong earnings, strategic collaborations, and a robust pipeline amid a market shift toward biologics.

AbbVie’s new shareholder shift highlights its battle against the Humira patent cliff, market‑access pressures, and M&A prospects—insights on future growth and strategy.

AbbVie’s $12 bn senior‑note deal fuels an Apogee Therapeutics acquisition, boosts R&D and reflects robust governance and philanthropy in immunology.

AbbVie’s $8 billion bond fuels Apogee’s anti‑inflammatory pipeline, gains UBRELVY reimbursement in Canada and expands BOTOX to masseter muscle—balancing debt, regulatory wins and aesthetic growth.

AbbVie Q2 2026 review: revenue up 5.7 %, earnings grow 18%, R&D stays lean, and analysts upgrade targets while patent expirations and biosimilar risk loom.

AbbVie beats earnings thanks to a surge in Skyrizi sales, but a costly Apogee acquisition forces a profit forecast cut, sparking investor worry about short‑term earnings drag.

AbbVie’s Q2 2026 earnings beat on Skyrizi and Rinvoq growth, yet its $5.3 billion Apogee deal trims EPS – a nuanced look at gains, integration costs and future upside.